- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01800565
First-Voided Urinary LH vs. GnRH-stimulation in Differentiating Slowly- From Rapidly Progressive-Precocious Puberty
Urinary LH in the Diagnosis of Precocious Puberty
Precocious puberty (PP) in girls is classically defined by the onset of secondary sexual characteristics before eight years of age, but subsequent pubertal maturation can be quite varied. In many girls, PP takes a rapid course of progression (rapidly progressive precocious puberty; RP-PP) with an early menarche and fusion of the epiphyseal growth plates, leading eventually to a reduced final height if not treated. In a subset of girls with PP however, the growth rate slows to normal for age, skeletal maturation progresses in accordance with chronological age and there is little to no risk of impairment of final height (slowly progressive precocious puberty; SP-PP). Other conditions of non-progressive PP include premature breast budding and unsustained PP that is characterized by a spontaneous regression of sexual precocity. Due to their benign course, slowly progressive (SP) PP and other non-progressive forms of PP do not warrant therapy with GnRH agonists. Differentiating these forms from RP-PP is therefore essential to prevent unnecessary intervention in a population that accounts for at least 50% of girls with PP. A distinction between these forms of PP may be difficult on clinical grounds however, since all these patients may present initially as isolated breast development.
The gold standard for the diagnosis of true (central) PP is the measurement of gonadotropins following GnRH stimulation test. There is however an overlap between prepubertal and early pubertal values and between girls with premature breast budding and progressive PP. It was suggested therefore that progressive pubertal development and growth acceleration should be documented over a 3- to 6-months period before GnRHa therapy in initiated.
More than a decade ago several studies demonstrated that urinary gonadotropins are age related and significantly increased during puberty. It has been suggested that urinary gonadotropins measurements can be used for differential diagnosis of pubertal disorders. This is based on the assumption that gradual elevation of nocturnal LH secretion prior to and at the onset of puberty can be reflected by first-voided urinary LH (ULH). In this prospective study, the investigators aimed to evaluate the value of first-voided ULH measurements in predicting pubertal course and differentiating SP-PP from RP-PP, by comparison to GnRH-stimulated gonadotropins.
Study Overview
Status
Conditions
Detailed Description
Precocious puberty (PP) in girls is classically defined by the onset of secondary sexual characteristics before eight years of age, but subsequent pubertal maturation can be quite varied. In many girls, PP takes a rapid course of progression (rapidly progressive precocious puberty; RP-PP) with an early menarche and fusion of the epiphyseal growth plates, leading eventually to a reduced final height if not treated. In a subset of girls with PP however, the growth rate slows to normal for age, skeletal maturation progresses in accordance with chronological age and there is little to no risk of impairment of final height (slowly progressive precocious puberty; SP-PP). Other conditions of non-progressive PP include premature thelarche and unsustained PP that is characterized by a regression of sexual precocity. Due to their benign course, slowly progressive (SP) PP and other non-progressive forms of PP do not warrant therapy with GnRH agonists. Differentiating these forms from RP-PP is therefore essential to prevent unnecessary intervention in a population that accounts for at least 50% of girls with PP. A distinction between these forms of PP may be difficult on clinical grounds however, since all these patients may present initially as isolated breast development.
The gold standard for the diagnosis of true (central) PP is the measurement of gonadotropins following GnRH stimulation test , where peak LH and peak LH/FSH ratio are the most valuable diagnostic parameters. There is however an overlap between prepubertal and early pubertal values and between girls with premature thelarche and progressive PP. It was suggested therefore that progressive pubertal development and growth acceleration should be documented over a 3- to 6-months period before GnRHa therapy in initiated.
More than a decade ago, along with the development of high-sensitive immunoassay for gonadotropins that replaced the RIA, Demir and colleagues have shown that urinary gonadotropins are age related and significantly increased during puberty. It has been suggested by others that urinary gonadotropins measurements can be used for differential diagnosis of pubertal disorders. This is based on the assumption that gradual elevation of nocturnal LH secretion prior to and at the onset of puberty can be reflected by first-voided urinary LH (ULH). In this prospective study, the investigators aimed to evaluate the value of first-voided ULH measurements in predicting pubertal course and differentiating SP-PP from RP-PP, by comparison to GnRH-stimulated gonadotropins.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Amnon Zung, MD
- Phone Number: 972-8-9441260
- Email: amzung2@bezeqint.net
Study Locations
-
-
-
Rehovot, Israel, 76100
- Recruiting
- Peditaric Endocrinology Unit, Kaplan Medical Center
-
Contact:
- Amnon Zung, MD
- Phone Number: 972-8-9441260
- Email: amzung2@bezeqint.net
-
Principal Investigator:
- Amnon Zung, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Onset of puberty after 3 years of age in boys and girls
- Onset of puberty before 8 years in girls and 9 years in boys
Exclusion Criteria:
- Non-central precocious puberty
- Congenital adrenal hyperplasia
- Enuresis nocturne
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: pubertal progression
A collection of first voided urine sample for the measurement of LH.
|
participants in this study will be studied by the standard GnRH stimulation test.
In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
participants in this study will be studied by the standard GnRH stimulation test.
In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identification of first-voided urinary LH cutoff for the detection of pubertal advancement by comparison with GnRH stimulated gonadotropins
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Levels first-voided urinary LH measurements in monitoring gonadotropin suppression during GnRHa therapy
Time Frame: 2 years
|
2 years
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identification of first-voided urinary LH cutoff for differentiating pseudothelarche from true breast budding, compared with GnRH stimulated gonadotropins
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Amnon Zung, MD, Pediatirc Endocrinology Unit, Kaplan Medical Center, affiliated with the Hebrew University of Jerusalem, Israel
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ULH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Precocious Puberty, Gonadotropin-dependent
-
Alkü Alanya Education and Research HospitalUnknownUterine Fibroid | Gonadotropin-Releasing Hormone-Dependent Precocious PubertyTurkey
-
AbbVieCompletedCentral Precocious Puberty (CPP)United States, Puerto Rico
-
Debiopharm International SARecruiting
-
Foresee Pharmaceuticals Co., Ltd.QPS Holdings LLC; Changchun GeneScience Pharmaceutical Co., Ltd.RecruitingPuberty; Precocious, CentralUnited States, China, Taiwan, Puerto Rico
-
IpsenCompleted
-
TakedaCompletedCentral Precocious PubertyChina
-
TakedaCompletedCentral Precocious PubertyChina
-
Debiopharm International SACompletedCentral Precocious PubertyUnited States, Chile, Mexico
-
Ruijin HospitalShanghai Children's Hospital; Shanghai Children's Medical Center; Xin Hua HospitalCompletedCentral Precocious Puberty
-
Daewoong Pharmaceutical Co. LTD.CompletedCentral Precocious PubertyKorea, Republic of
Clinical Trials on Measurement of LH in first-voided urine
-
Institute of Tropical Medicine, BelgiumSRI International; Sihanouk Hospital Center of HOPECompletedSystemic Inflammatory Response Syndrome | Melioidosis | Suspected or Confirmed Bloodstream InfectionsCambodia
-
Swiss Paraplegic Centre NottwilRecruitingBladder Cancer | Spinal Cord InjurySwitzerland
-
Changi General HospitalRecruitingObstructive Sleep Apnea | Pheochromocytoma | Catecholamine; SecretionSingapore
-
University Hospital, BordeauxRecruitingMen Who Have Sex With MenFrance
-
Marmara UniversityCompletedVenous Insufficiency | Foot Drop (Acquired)Turkey
-
Nantes University HospitalCompletedNeonatal Acute Renal Failure in PretermFrance
-
Shaare Zedek Medical CenterCompletedUrinary Tract Infection
-
Assiut UniversityNot yet recruitingGalectin-3 and Pemphigus
-
Meir Medical CenterWithdrawnUrinary Incontinence | Vulvar Pruritus | Vulvar Contact DermatitisIsrael
-
Lund UniversitySkane University HospitalNot yet recruitingPatient Participation | Heart Rate Determination